

- 1- B. Khalil and J.-C. Liévens. Mitochondrial quality control in amyotrophic lateral sclerosis: towards a common pathway? **Neural Regen Res**, 2017, in press.
- 2- B. Khalil, M.-J. Cabirol-Pol, L. Miguel, A.J. Whitworth, M. Lecourtois and J.-C. Liévens. Enhancing Mitofusin/Marf ameliorates neuromuscular dysfunction in *Drosophila* models of TDP-43 proteinopathies. **Neurobiol Aging**, 2017, 54, 71–83.
- 3- M.-T. Besson, K. Alegría, P. Garrido-Gerter, L. F. Barros and J.-C. Liévens. Enhanced neuronal glucose transporter expression reveals metabolic choice in a HD *Drosophila* model. **PloS One**, 2015, 10, e0118765.
- 4- B. Khalil, N. El Fissi, A. Aouane, M.-J. Cabirol-Pol, T. Rival and J.-C. Liévens. PINK1-induced mitophagy promotes neuroprotection in Huntington's disease. **Cell Death Dis.**, 2015, 6, e1617.
- 5- M. Macchi, N. El Fissi, R. Tufi, M. Bentobji, J.-C. Liévens, L.M. Martins, J. Royet and T. Rival. The *Drosophila* inner-membrane protein PMI controls crista biogenesis and mitochondrial diameter. **J. Cell. Sci.** 2013,126, 814-24.
- 6- P. Dupont, M.-T. Besson, J. Devaux and J.-C. Liévens. Reducing canonical Wingless/Wnt signaling pathway confers protection against mutant Huntingtin toxicity in *Drosophila*. **Neurobiol. Dis.**, 2012, 47, 237-247.
- 7- M.-T. Besson, P. Dupont, Y.-W. C. Fridell and J.-C. Liévens. Increased energy metabolism rescues glia-induced pathology in a *Drosophila* model of Huntington's disease. **Hum. Mol. Genet.**, 2010, 19, 3372-3382.
- 8- J.-C. Liévens, M. Iché, M. Laval, C. Faivre-Sarrailh and S. Birman. AKT-sensitive or insensitive pathways of toxicity in glial cells and neurons in *Drosophila* models of Huntington's disease. **Hum. Mol. Genet.**, 2008, 17, 882-894.
- 9- J.-C. Liévens and S. Birman. Astrocytes in Huntington's chorea: accomplice or guilty of the neuronal death. **Med. Sci. (Paris)**, 2007, 23, 845-849.
- 10- L. De Yeba, Y. Malpesa, G. Ursu, M. Pugliese, J.-C. Liévens, L. Kerkerian-Le Goff and N. Mahy. Dissociation between hippocampal neuronal loss, astroglial and microglial reactivity after pharmacologically induced reverse glutamate transport. **Neurochem. Int.**, 2006, 49, 691-697.
- 11- J.-C. Liévens, T. Rival, M. Iché, H. Chneiweiss and S. Birman. Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in *Drosophila*. **Hum. Mol. Genet.**, 2005, 14, 713-724.
- 12- J.-C. Liévens and S. Birman. Huntington's chorea in *Drosophila* and mouse discloses new tracks for therapy. **Med. Sci. (Paris)**, 2003, 19, 593-599.
- 13- J.-C. Liévens, B. Woodman, A. Mahal and G. Bates. Abnormal phosphorylation of synapsin I predicts a neuronal transmission impairment in the R6/2 Huntington's disease transgenic mice. **Mol. Cell. Neurosci.**, 2002, 20, 638-648.

- 14- J.-C. Liévens, B. Woodman, A. Mahal, O. Spasic-Boskovic, D. Samuel, L. Kerkerian-Le Goff and G. Bates. Impaired glutamate uptake in R6 Huntington's disease transgenic mice. **Neurobiol. Dis.**, 2001, 8, 807-821.
- 15- B. Di Cara, N. Dusticier, C. Forni, J.-C. Liévens and A. Dazuta. Serotonin depletion produces long lasting increase in striatal glutamatergic transmission. **J. Neurochem.**, 2001, 78, 240-248.
- 16- J.-C. Liévens, P. Salin, A. Nieoullon and L. Kerkerian-Le Goff. Nigrostriatal denervation does not affect glutamate transporter mRNA expression but subsequent levodopa treatment selectively increases GLT1 mRNA and protein expression in the rat striatum. **J. Neurochem.**, 2001, 79, 893-902.
- 17- J.-C. Liévens, P. Salin, L. Had-Aissouni, N. Mahy and L. Kerkerian-Le Goff. Differential effects of corticostriatal and thalamostriatal deafferentation on expression of the glutamate transporter GLT1 in the rat striatum. **J. Neurochem.**, 2000, 74, 909-919.
- 18- J.-C. Liévens, F. Bernal, C. Forni, N. Mahy and L. Kerkerian-Le Goff. Characterization of Striatal Excitotoxic Lesions Produced by Glutamate Uptake Alteration: Cell Death, Reactive Gliosis and Changes in GLT1 and GADD45 mRNA Expression. **Glia**, 2000, 29, 222-232.
- 19- J.-C. Liévens, M. Dutertre, C. Forni, P. Salin and L. Kerkerian-Le Goff. Continuous administration of the glutamate uptake inhibitor *L-trans*-pyrrolidine-2,4-dicarboxylate produces striatal lesion. **Mol. Brain Res.**, 1997, 50, 181-189.